When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there’s not enough time to set off the cell’s alarm system.
Now, a Loyola University Chicago study has discovered the protein that helps the virus travel so fast. Researchers found that without this protein, the virus became stranded in the cytoplasm, where it was detected by the viral defense system. (The cytoplasm is the portion of the cell outside the nucleus.)
“By preventing its normal movement, we essentially turned HIV-1 into a sitting duck for cellular sensors,” said Edward M. Campbell, PhD, corresponding author of the study, published in the Proceedings of the National Academy of Sciences. Campbell is an associate professor in the Department of Microbiology and Immunology of Loyola University Chicago Stritch School of Medicine.
HIV-1 infects and kills immune system cells, including T cells and macrophages that were used in the study. This cripples the immune system, making the patient vulnerable to common bacteria, viruses and other pathogens that are usually harmless in people with healthy immune systems.
After HIV-1 enters a cell, it has to work its way through the cytoplasm to the nucleus. Once inside the nucleus, HIV-1 takes control of the cell and makes additional HIV-1 copies. But getting through the cytoplasm is not easy. Cytoplasm consists of fluid that is thick with proteins and structures such as mitochondria. “Something the size of a virus cannot just diffuse through the cytoplasm,” Campbell said. “It would be like trying to float to the bathroom in a very crowded bar. You need to have a plan.”
HIV-1 is able to get to the nucleus quickly via tubular tracks called microtubules. The virus attaches itself to a molecular motor called dynein, which moves down the microtubule like a train car on tracks.
Campbell and colleagues discovered the “ticket” HIV-1 needs to get on the train — a protein called bicaudal D2. HIV-1 binds to bicaudal D2, which recruits the dynein molecular motor. The dynein then transports HIV-1 towards the nucleus.
The finding raises the possibility of developing a drug that would prevent HIV-1 from binding to bicaudal D2, thus stranding the virus in the cytoplasm. This would not only prevent infection, but also give the cell time to turn on antiviral genes that would protect it and neighboring cells from infection.
Learn more: Study suggests a way to stop HIV in its tracks
The Latest on: HIV
- Project aims to address HIV and substance use in Jefferson County youthon August 11, 2020 at 11:07 am
Project LEAP will make novel use of integrated patient navigation and student champions to help high-risk young residents. Jefferson County is home to less than 15% of Alabama’s population, yet it was ...
- AUM LifeTech awarded NIH grant to develop HIV therapy using RNA targeting technology, commits additional resources to COVID-19 researchon August 11, 2020 at 7:23 am
AUM LifeTech, Inc., a Philadelphia based preclinical stage biotechnology company, has received a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious ...
- The Program That Keeps Half a Million People With HIV Alive and Well Turns 30 This Monthon August 11, 2020 at 7:10 am
We spoke to two experts about the origin, evolution, and future of the Ryan White CARE Act, passed on August 18, 1990.
- Gilead Sciences Says China NMPA Approves Truvada For HIV Pre-Exposure Prophylaxison August 11, 2020 at 6:10 am
In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents ...
- China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)on August 11, 2020 at 5:17 am
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg ...
- OPINION: Why SisterLove pushes for more women in HIV clinical trialson August 11, 2020 at 4:33 am
A month after leaving the Atlanta Feminist Women’s Health Center in 1989, Dázon Dixon Diallo founded SisterLove Inc., the oldest women-centered HIV and sexual and reproductive justice advocacy ...
- Global HIV-AIDS Diagnostics Market Set for Rapid Growth in the Forecast Period 2020-2026 - Zion Market Researchon August 11, 2020 at 1:20 am
Zion Market Research Reports added Latest Research Report titled " Global HIV-AIDS Diagnostics Market Set for Rapid Growth in the Forecast Period 2020-2026 - Zion Market Research " to its Large Report ...
- South Africa’s poor scramble for anti-HIV drugs amid coronaviruson August 11, 2020 at 12:53 am
When her regular clinic ran out of her government-funded HIV medications amid South Africa’s COVID-19 lockdown, Sibongile Zulu panicked. A local pharmacy had the drugs for $48, but ...
- South Africa’s poor scramble for anti-HIV drugs amid viruson August 11, 2020 at 12:07 am
When her regular clinic ran out of her government-funded HIV medications amid South Africa’s COVID-19 lockdown, Sibongile Zulu panicked. A local pharmacy had the drugs for ...
- South Africa’s poor scramble for anti-HIV drugs amid virus | Raleigh News & Observeron August 10, 2020 at 11:26 pm
Across Africa and around the world, the COVID-19 pandemic has disrupted the supply of antiretroviral drugs to many of the more than 24 million people who take them, endangering their lives.
via Google News and Bing News